FDA Data: Breakthrough Program Accepted 45% Of Applicants Since 2015

Data from the US Food and Drug Administration shows that the agency has granted 853 breakthrough device applications since 2015, out of 1,909 applications. The acceptance rate has varied from 33% in 2016 to 72% in 2017, with acceptance rates in recent years hovering around the 40% mark.

Young businessman breaking through a wall.
• Source: Shutterstock

Interested in the US Food and Drug Administration's breakthrough devices pathway? The odds may not be in your favor. Data from the agency shows that of almost 2,000 applications to the program and its predecessor since 2015, only 853 -- about 45% were granted the designation, with the other applications being either denied or withdrawn.

To qualify for the program, devices must provide more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

Medtech Must Address AI Risks Now Or Jeopardize Its Future Potential, Expert Warns

 

Urgent action is needed to address gaps in how risks from medical devices and diagnostics utilizing AI are identified, mitigated and managed. So says James Pink, renowned medtech regulatory expert in an interview with Medtech Insight.

No EUDAMED, No Market: ‘Waiting Until Mandatory Deadline Is Risky’

 

EirMed CEO Richard Houlihan warns that EUDAMED (the European database on medical devices) publication delays may harm medical device manufacturers. Currently, only a fraction of the required uploads have occurred, creating potential compliance risks as the mandatory deadline approaches.

Medical Device Recalls Down In Q1 For Lowest Quarterly Count In 3 Years. But Will It Last?

 

Despite a surge in product recalls across five key industries in the first quarter of the year, medical device recalls were down, according to Sedgwick’s latest recall index. But the firm noted they’ve since ticked up.

23andMe Genetic Tests Among 12 New FDA Classifications

 
• By 

A late-August batch of device classifications from the US FDA includes genetic tests from 23andMe, hand-held spinal surgery tools, and several IVDs.

More from Policy & Regulation

No EUDAMED, No Market: ‘Waiting Until Mandatory Deadline Is Risky’

 

EirMed CEO Richard Houlihan warns that EUDAMED (the European database on medical devices) publication delays may harm medical device manufacturers. Currently, only a fraction of the required uploads have occurred, creating potential compliance risks as the mandatory deadline approaches.

Oura Gets Competitors Banned From US Market, But Faces Ultrahuman Countersuit

 
• By 

The US International Trade Commission has banned smart rings from Ultrahuman and RingConn after Oura Health's patent infringement case. Ultrahuman countersued, claiming Oura infringes its intellectual property. Sales and marketing of the affected rings will cease on October 22.

A Decade Of Breakthrough Devices: Cardiac And Orthopedic Products Dominate FDA Designations

 

The US FDA has provided an update on its breakthrough devices program, now 10 years running. Cardiac, orthopedic, and neurological devices have received the most designations, while only one has been awarded to an obstetrics/gynecology product.